N. Johnson

Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer

N. Bosanquet, P. Koch, K. Copley-Merriman, 1995, Anti-cancer drugs.

Cost effectiveness of 5‐hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron

N. Bosanquet, N. Johnson, 1995, Anti-cancer drugs.

The epidemic of Alzheimer's disease. How can we manage the costs?

N. Bosanquet, N. Johnson, T. Davis, 2000, PharmacoEconomics.

The Epidemic of Alzheimer’s Disease

N. Bosanquet, N. Johnson, T. Davis, 2000, PharmacoEconomics.

Economic value of gemcitabine in non-small cell lung cancer.

C. Copley-Merriman, J. Sacristán, N. Bosanquet, 1996, Seminars in oncology.